We integrate throughout the continuous investment process – from technological viability to market commercialisation and expansion.
Our investment drive focuses on disruptive medical technology leading to healthier living for tomorrow’s ageing population, especially in the field of digital diagnostics and therapeutics.
From pre-seed to step-up rounds to more mature institutional investment funds (like TZPBC Healthy Ageing Impact Venture Fund).
Founders’ equity structure, team structure, funding stewardship, and investor relations are important considerations we help advise.
Through our Market Readiness Platform, our invested technologies are validated in proving grounds of hospital and nursing home environments to strengthen commercialisation viability further.
We integrate throughout the continuous investment process – from technological viability to market commercialisation and expansion.
Our investment drive focuses on disruptive medical technology leading to healthier living for tomorrow’s ageing population, especially in the field of digital diagnostics and therapeutics.
From pre-seed to step-up rounds to more mature institutional investment funds (like TZPBC Healthy Ageing Impact Venture Fund).
Founders’ equity structure, team structure, funding stewardship, and investor relations are important considerations we help advise.
Through our Market Readiness Platform, our invested technologies are validated in proving grounds of hospital and nursing home environments to strengthen commercialisation viability further.
Our TECHNOLOGICAL PARTNERSHIPS and ventures specialise in brain health digital therapeutics, next-generation PET scans, and higher-resolution 3D ultrasound imaging.
Brain Computer Interface (BCI) centres on ADHD, Parkinson’s and dementia therapeutics.
Photo-Neuro Intervention (PNI) enables photoactive treatments inside the brain.
Next-generation organ-targeted PET devices that are mobile, have a higher definition, sensitivity and low dose.
Next-generation point-of-care 3D Ultrasound.
As our population ages at a faster rate than before, more medical innovations are focusing on proactive early detection and disease deferment increasing better quality aged living.
Our technology portfolio reflects this trend of seeking and employing more digital diagnostics and therapeutics for the aged especially in the brain health space.
The invested technology focuses on sleep disorders, stroke, and ADHD (Attention Deficit Hyperactivity Disorder).
Its core technology is a platform OS that empowers health care professionals, researchers and third-party developers with an Artificial Intelligence (AI) driven platform with the ability to analyse users’ brain signals, measuring mental states including but not limited to attention, relaxation, mental workload and fatigue. The holistic platform, coupled with its other offerings, reveals numerous avenues as complementary options for ADHD children, stroke rehabilitation, cognitive rehabilitation and many other neurological challenges.
The invested technology focuses on sleep disorders, stroke, and ADHD (Attention Deficit Hyperactivity Disorder).
Its core technology is a platform OS that empowers health care professionals, researchers and third-party developers with an Artificial Intelligence (AI) driven platform with the ability to analyse users’ brain signals, measuring mental states including but not limited to attention, relaxation, mental workload and fatigue. The holistic platform, coupled with its other offerings, reveals numerous avenues as complementary options for ADHD children, stroke rehabilitation, cognitive rehabilitation and many other neurological challenges.
Our invested technology is a one-of-a-kind patented implantable light-activated therapy system capable of suppressing or halting the recurrence of neurodegenerative diseases, including:
Targeted wireless photo-stimulation has been demonstrated to induce neuroprotective effects and is a revolutionary development and versatile PIN platform to enable photoactive treatments inside the brain.
Image of the same breast of the same patient. Left image – normal scan. Right image using low dose PET, hi-definition, organ target imaging.
This next-generation disruptive imaging technology creates better diagnostic opportunities in neurology, oncology, cardiology, and rheumatology over current PET scan capabilities
Left : Image of the 3DUS scanner used to image the knee.
Right : Cross-section of a wrist 3DUS acquisition of a knee displaying relevant anatomical structures and mild effusion synovitis.
POC diagnostic imaging systems are brought to the patient rather than moving the patient to the hospital. Three-dimensional (3DUS) diagnostic imaging systems are based on significant unmet clinical needs and the lack of availability of integrated diagnostic POC systems.
TeleHealth systems will be the benchmark of future patient care. However, it must transcend just video conferencing features to real-time digital solutions coupled with breakthrough medical technologies.
TZ Healthcare envisages the next generation Technology-as-a-Service (TaaS) TeleHealth systems to include such technologies as brain health, sleep and preventive care, and next-generation imaging systems. As a result, Telecare systems can be more cost-effective through technology integration, efficiency, and scale.
TZ Healthcare sees TeleHealth systems to include TeleMental, TeleSleep, TeleImaging, etc., as more medical technologies arise, driven by advancing AI-powered data systems.
As a result, Telecare systems can be more cost-effective through technology integration, and effectiveness for both clinicians and caregivers.
TeleHealth systems will be the benchmark of future patient care. However, it must transcend just video conferencing features to real-time digital solutions coupled with breakthrough medical technologies.
TZ Healthcare envisages the next generation Technology-as-a-Service (TaaS) TeleHealth systems to include such technologies as brain health, sleep and preventive care, and next-generation imaging systems. As a result, Telecare systems can be more cost-effective through technology integration, efficiency, and scale.
TZ Healthcare sees TeleHealth systems to include TeleMental, TeleSleep, TeleImaging, etc., as more medical technologies arise, driven by advancing AI-powered data systems.
As a result, Telecare systems can be more cost-effective through technology integration, and effectiveness for both clinicians and caregivers.
The greatest asset Singapore offers to Asia is its population. Singapore represents 80% of the ethnic people of Asia. As a crucible for medical innovation, systems, research and finance, the ability to innovate and represent the rest of Asia is a significant strategic asset. Singapore-developed medical innovations – readied for Asia and the world.
Medical health research for ethnic Asians is multiplying, complementing and growing the diagnostic and therapeutic regimes of western-based solutions. The more significant ensuing opportunity is for AI-powered Asian databases will be the new Asian medical frontier.
Singapore’s pro-business environment offers increasing coordinated efficiencies among the various stakeholders, both private and public sectors, regulatory, academia, and technologists.
According to Enterprise Singapore (ESG), there is growing diversity of Singapore firms taking advantage of connectivity in the Guangdong-Hong Kong-Macao Greater Bay Area.
Greater Bay Area (GBA) accelerated their push into new hi-tech manufacturing and industries, which will shape the economic and manufacturing powerhouse of the 21st century, contributing more than 10% of China’s GDP. GBA’s compelling proposition is a highly skilled talent pool and a pro-tech innovation environment.
The Singapore-Guangdong Collaboration Council (SGCC) was established in 2009 to foster partnerships focused on innovative technologies and “knowledge-intensive’ projects.
ASEAN is China’s largest trading partner, with Singapore as the leading trade and financial centre, having a pivotal role in that relationship. China has had a positive experience adapting Singapore’s management models. In particular, the healthcare system of Singapore, with its forward-thinking technology integration and well-known cost-effectiveness, will have an advantage in playing a leading role in the healthcare system.
According to Enterprise Singapore (ESG), there is growing diversity of Singapore firms taking advantage of connectivity in the Guangdong-Hong Kong-Macao Greater Bay Area.
Greater Bay Area (GBA) accelerated their push into new hi-tech manufacturing and industries, which will shape the economic and manufacturing powerhouse of the 21st century, contributing more than 10% of China’s GDP. GBA’s compelling proposition is a highly skilled talent pool and a pro-tech innovation environment.
The Singapore-Guangdong Collaboration Council (SGCC) was established in 2009 to foster partnerships focused on innovative technologies and “knowledge-intensive’ projects.
ASEAN is China’s largest trading partner, with Singapore as the leading trade and financial centre, having a pivotal role in that relationship. China has had a positive experience adapting Singapore’s management models. In particular, the healthcare system of Singapore, with its forward-thinking technology integration and well-known cost-effectiveness, will have an advantage in playing a leading role in the healthcare system.
These include medical academia, medical practitioners, healthcare entrepreneurs, investment funds, and financial advisors from significant healthcare centres in the US, Canada, the UK, Finland, Greater China, Singapore, and Hong Kong.
Get in touch with us for partnership and investor relations matters.
Email us or submit this form.
Tan Wee Theng, a Singaporean has worked in China since 1996. Wee Theng keeps abreast with Chinese affairs, trends, and ties both in the private and public sectors. His experience as a Corporate Executive spans more than 30 years working in North America and the Asia Pacific. In his last corporate role, he was the President of Intel China and a Vice President of Intel Corporation.
Wee Theng was one of the first foreigners in China to be granted permanent resident status in 2004. Among his significant accomplishments in China, Tan was instrumental in influencing corporate investments in China of the Test and Assembly plant in Chengdu, and a fabrication plant in Dalian. These investments were worth more than US$ 3 Billion.
After retiring from Intel in 2008, he started his own business advisory company, Tan & Associates, operating from both Hong Kong and Beijing. Among his clients are Fortune 500 companies based in China and Asia Pacific advising.
Wee Theng is the founding partner of TZ-Healthcare Management, a venture integrator that focuses on strategic healthcare technology investments in the Asian region.
Jackson brings 25 years of successful track record of incubating and financing new ventures. After founding an Internet Service Provider and building up financial platform for Canadian-listed mining companies, Jackson partnered with the Vancouver Stock Exchange to organize the first International Mining Exhibition in China in 1996 resulting in the participation of over 100 international mining companies.
Jackson’s foresight in the potential of the biotech industry established him as a pioneer in the 1990s when he founded Dragon Pharmaceutics and listed it on Nasdaq in 1998 and spearheaded the company’s international financing and acquisition of a manufacturing plant in China when biotech was still a restricted industry.
Jackson then partnered with the Chairman of the GEM Board of the Hong Kong Stock Exchange to form a financial platform for early-stage life science ventures in China, Hong Kong, Canada, and the USA. His keen insights into the potential of ASEAN and China’s One Belt One Road policy have brought him to a new frontier of hi-tech industries, especially healthcare in the region.
Dr Fester is currently one of CIMTEC’s Chief Scientific Officers and its Centre Director. In 2010, he became the Chief Scientific Officer, Centre Director and acting CEO of the newly formed Centre for Imaging Technology Commercialization – a federally funded Centre of Excellence in Commercialization and Research.
Currently, he holds a Canada Research Chair-Tier 1 in Biomedical Engineering. He is the first recipient of the Premier’s (Ontario) Discovery Award for Innovation and Leadership (2007), the Hellmuth Prize for Achievement in Research at the UWC (2008) and the Canadian Organization of Medical Physicists (COMP) Gold Medal Award (2010). In 2011 he was inducted into the Canadian Academy of Health Sciences.
Dr Fenster’s research has resulted in more than 300 papers in peer reviewed journals, more than 40 patents filed and the formation of four companies in London based on research in his laboratory. In addition, some of his patents have been licensed to 13 different companies, which have commercialized them for worldwide distribution. He has developed image-based interventional system used to perform minimally invasive interventions to treat cancer with an aim of cancer control and maintaining quality of life. His projects include – 3D-ultrasound-guided prostate biopsy, 3D-ultrasound-guided cervical and breast cancer brachytherapy; 3D-ultrasound-guided liver focal ablation; and MR-guided focal prostate cancer ablation.
Stephanie has over 25 years of experience in direct investment, M&A and corporate finance. She was Head of Business Development at Melco International Development Ltd. from 2006 to 2017, directed the Group’s international business expansion and led the acquisitions of various operational assets.
Before Melco, she was one of the originating members of HUTCHMED China Limited, building up a portfolio of healthcare investments for the Group currently listed on HKEX, LSX and Nasdaq. She also worked for INVESCO Asia and Arthur Andersen & Co.
Ronald’s focus has been branding strategy and its articulation in automobiles, medical products, military recruitment, and fast-moving consumer products.
His first introduction to healthcare was at Johnson & Johnson working on pharmaceuticals, medical devices, and consumer brands. He went on to work in multinational communication companies – Ogilvy & Mather and Dentsu, Young & Rubicam guiding and rationalising branding strategies for client brands. Wanting to exercise his entrepreneurial desire, he managed and co-owned a Singapore branding agency, Zender Fang Associates – where we saw the transition into the digital era of creative communication. Strategy experience couldn’t be more helpful in building his own company brand.
Answering the call for entrepreneurial diversity, Ronald co-founded a web application software development company – Fynch Consulting. A new world of intranet web applications was created – Online Business Continuity Planning and content management and marketing system for Volkswagen APAC, online inventory, and marketing systems for Denso APAC (automotive parts), and our own propriety Pilot Scheduling System (Infinet) for regional airlines.
Ronald’s healthcare experience has come full circle managing the strategic branding and communication of venture integrator TZ-Healthcare.